Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.67 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760574 | 0.84 | — | — | |
| SCHEMBL3700532 | 0.80 | TET2 (1.00) | EGLN1TET2MGAMGAASI | |
| SCHEMBL16133035 | 0.80 | EGLN1 (1.00) | EGLN1TET2ALDH1A1TGFBR1MAPT | |
| SCHEMBL1979843 | 0.79 | EGLN1 (0.70) | EGLN1TET2ALDH1A1MGAMGAA | |
| SCHEMBL10315772 | 0.76 | EGLN1 (0.37) | EGLN1TET2ALDH1A1MGAMGAA | |
| SCHEMBL3269747 | 0.74 | — | — | |
| SCHEMBL17183911 | 0.74 | EGLN1 (0.41) | EGLN1TET2ALDH1A1MGAMGAA | |
| SCHEMBL22314666 | 0.73 | TET2 (0.69) | EGLN1TET2GAATGFBR1MAPT | |
| SCHEMBL18039340 | 0.73 | TET2 (0.69) | EGLN1TET2ALDH1A1MGAMGAA | |
| SCHEMBL15535846 | 0.72 | TGFBR1 (0.39) | EGLN1TET2ALDH1A1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-8722688-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| CN-102906080-A | Compounds for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2013-01-30 | — | — | CN | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | EGLN1 2686/4885TET2 4221/4885ALDH1A1 239/4885 |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | EGLN1 2686/4885TET2 4221/4885ALDH1A1 239/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | EGLN1 914/4885TET2 2486/4885ALDH1A1 1155/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | EGLN1 2686/4885TET2 4221/4885ALDH1A1 239/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | EGLN1 2686/4885TET2 4221/4885ALDH1A1 239/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | EGLN1 2686/4885TET2 4221/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.